|
| Press Releases |
|
 |
|
| Friday, April 3, 2020 |
|
|
아방스 클리니컬, APAC 바이오테크 고객사들이 임상시험을 위해 호주를 선택하는 주요 이유 밝혀 |
| 호주의 임상시험수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 클라이언트 온보딩 피드백을 토대로 APAC 바이오테크 기업들이 초기 임상시험을 위해 호주를 선택하는 주요 이유를 오늘 밝혔다. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
澳大利亞CRO, Avance Clinical公司在COVID-19疫苗和臨床試驗治療方案方面具有得天獨厚的優勢 |
| 澳大利亞CRO Avance Clinical今天表示，澳大利亞快速的監管審批環境，關鍵意見領袖的專業知識和高質量的臨床研究中心，以及頗具吸引力的40%的政府臨床試驗支出退稅，所有這一切都意味著Avance具有得天獨厚的優勢，能夠使緊迫的COVID-19試驗速見成效。 more info >> |
|
|
澳大利亚CRO, Avance Clinical公司在COVID-19疫苗和临床试验治疗方案方面具有得天独厚的优势 |
| 澳大利亚CRO Avance Clinical今天表示，澳大利亚快速的监管审批环境，关键意见领袖的专业知识和高质量的临床研究中心，以及颇具吸引力的40%的政府临床试验支出退税，所有这一切都意味着Avance具有得天独厚的优势，能够使紧迫的COVID-19试验速见成效。 more info >> |
|
|
호주 임상시험수탁기관인 아방스 클리니컬, COVID-19 백신 및 치료제 개발을 위한 임상시험에 독보적 위치 점유 |
| 호주의 임상시험수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 호주의 빠른 규제 승인 환경과 주요 오피니언 리더들의 전문성, 고품질 임상 연구소 및 임상시험 지출에 대해 정부가 지급하는 40%의 보조금 등으로 인해 자신들이 COVID-19 관련 임상시험에서 신속히 결과를 낼 수 있는 유리한 위치에 있다고 오늘 밝혔다. more info >> |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
OSL Lists State-Supervised Gold-Backed Stablecoin USDKG as Platform Expands Asia's Digital Asset Ecosystem
May 22, 2026 23:30: JST
|
|
|
OSL Lists State-Supervised Gold-Backed Stablecoin USDKG as Platform Expands Asia's Digital Asset Ecosystem
May 22, 2026 22:30 HKT/SGT
|
|
|
Six Factors to Consider When Opting for a Credit Line in Singapore
May 22, 2026 19:05 HKT/SGT
|
|
|
Patents Build Solid Barriers, Technologies Achieve All-Round Breakthroughs, New Vision Leads the New Track of AR Interaction
May 22, 2026 18:46: JST
|
|
|
Patents Build Solid Barriers, Technologies Achieve All-Round Breakthroughs, New Vision Leads the New Track of AR Interaction
May 22, 2026 17:46 HKT/SGT
|
|
|
天辰生物通過聆訊：深耕過敏與自身免疫領域 臨床療效全面領先
May 22, 2026 16:32 HKT/SGT
|
|
|
天辰生物通过聆讯：深耕过敏与自身免疫领域 临床疗效全面领先
May 22, 2026 16:32 HKT/SGT
|
|
|
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
May 22, 2026 11:05: JST
|
|
|
雲頂新耀獲主要股東康橋資本增持 全球化佈局有望持續受益
May 22, 2026 10:59 HKT/SGT
|
|
|
GTJAI Won Two Awards at HR Asia 2026
May 22, 2026 10:49 HKT/SGT
|
|
|
國泰君安國際斬獲HR Asia 2026年度兩項大獎
May 22, 2026 10:49 HKT/SGT
|
|
|
国泰君安国际斩获HR Asia 2026年度两项大奖
May 22, 2026 10:49 HKT/SGT
|
|
|
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
May 22, 2026 10:05 HKT/SGT
|
|
|
云顶新耀获主要股东康桥资本增持 全球化布局有望持续受益
May 22, 2026 10:05 HKT/SGT
|
|
|
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 0:23 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
